Chapters

Transcript

Video

Ben Schlechter, MD Presents Details on the Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Solid Tumors

A phase I/II Trial investigating safety and efficacy of autologous TAC T cells targeting HER2 in response or refractory solid tumors.


Published

September 23, 2022

Created by

Dana-Farber

Related Presenters

Benjamin L. Schlechter, MD

Benjamin L. Schlechter, MD

Medical Oncology

Dr. Schlechter is a medical oncologist who specializes in gastrointestinal cancers including colorectal cancer, anal cancer, pancreatic cancer, and neuroendocrine cancers, among others.

View full profile